{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:22:20Z","timestamp":1788355340897,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Transplantation"],"published-print":{"date-parts":[[2024,6]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n We hypothesized that alemtuzumab use is safe in pediatric kidney transplant recipients (KTRs) with equivalent long\u2010term outcomes compared to other induction agents.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Using pediatric kidney transplant recipient data in the UNOS database between January 1, 2000, and June 30, 2022, multivariate logistic regression, multivariable Cox regression, and survival analyses were utilized to estimate the likelihoods of 1st\u2010year and all\u2010time hospitalizations, acute rejection, CMV infection, delayed graft function (DGF), graft loss, and patient mortality among recipients of three common induction regimens (ATG, alemtuzumab, and basiliximab).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n There were no differences in acute rejection or graft failure among induction or maintenance regimens. Basiliximab was associated with lower odds of DGF in deceased donor recipients (OR 0.77 [0.60\u20130.99],\n p<\/jats:italic>\n \u2009=\u2009.04). Mortality was increased in patients treated with steroid\u2010containing maintenance (HR 1.3 [1.005\u20131.7]\n p<\/jats:italic>\n \u2009=\u2009.045). Alemtuzumab induction correlated with less risk of CMV infection than ATG (OR 0.76 [0.59\u20130.99],\n p<\/jats:italic>\n \u2009=\u2009.039). Steroid\u2010containing maintenance conferred lower rate of PTLD compared to steroid\u2010free maintenance (HR 0.59 [0.4\u20130.8]\n p<\/jats:italic>\n \u2009=\u2009.001). Alemtuzumab was associated with less risk of hospitalization within 1\u2009year (OR 0.79 [0.67\u20130.95]\n p<\/jats:italic>\n \u2009=\u2009.012) and 5\u2009years (HR 0.54 [0.46\u20130.65]\n p<\/jats:italic>\n \u2009<\u2009.001) of transplantation. Steroid maintenance also decreased 5\u2009years hospitalization risk (HR 0.78 [0.69\u20130.89]\n p<\/jats:italic>\n \u2009<\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Pediatric KTRs may be safely treated with alemtuzumab induction without increased risk of acute rejection, DGF, graft loss, or patient mortality. The decreased risk of CMV infections and lower hospitalization rates compared to other agents make alemtuzumab an attractive choice for induction in pediatric KTRs, especially in those who cannot tolerate ATG.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/petr.14783","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T05:34:10Z","timestamp":1716183250000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Alemtuzumab induction is associated with decreased hospitalization rates in pediatric kidney transplant: A\n UNOS<\/scp>\n data review for safety and outcomes with common induction regimens"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3987-6523","authenticated-orcid":false,"given":"Emmanuel","family":"Aydin\u2010Ghormoz","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Albany Medical Center Albany New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Division of Transplant Surgery, Department of General Surgery, Erie County Medical Center University at Buffalo Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8722-0898","authenticated-orcid":false,"given":"Naoru","family":"Koizumi","sequence":"additional","affiliation":[{"name":"Schar School of Policy and Government George Mason University Arlington Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-3690","authenticated-orcid":false,"given":"Meng\u2010Hao","family":"Li","sequence":"additional","affiliation":[{"name":"Schar School of Policy and Government George Mason University Arlington Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9029-2438","authenticated-orcid":false,"given":"Geovani","family":"Faddoul","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Albany Medical Center Albany New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14077"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16982"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00879.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12159"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12253"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.07.050"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12941"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12048"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.01987.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13685"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001416"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13925"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13928"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-008-0088-z"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001573"}],"container-title":["Pediatric Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/petr.14783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T09:29:33Z","timestamp":1716802173000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/petr.14783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/petr.14783"],"URL":"https:\/\/doi.org\/10.1111\/petr.14783","archive":["Portico"],"relation":{},"ISSN":["1397-3142","1399-3046"],"issn-type":[{"value":"1397-3142","type":"print"},{"value":"1399-3046","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"2023-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14783"}}